医学
呼吸系统
重症监护室
呼吸衰竭
呼吸道感染
下呼吸道感染
儿科
急诊医学
重症监护
重症监护医学
住院
帕利珠单抗
免疫
气道
新生儿重症监护室
呼吸道疾病
呼吸道
急性呼吸衰竭
呼吸道疾病
咨询委员会
毛细支气管炎
病毒
呼吸道感染
插管
作者
Laura Divens Zambrano,Regina M. Simeone,Margaret M. Newhams,Amanda B. Payne,Natasha Halasa,Amber O. Orzel-Lockwood,Jemima M. Calixte,Satoshi Kamidani,Hillary Crandall,Melissa A. Cameron,Jennifer E. Schuster,Aline B. Maddux,Kathleen Chiotos,Katherine Irby,Steven L. Shein,Mary Allen Staat,Lora Martin,Samina S. Bhumbra,Ryan A. Nofziger,Jigar Chauhan
标识
DOI:10.15585/mmwr.mm7437a1
摘要
Respiratory syncytial virus (RSV) is a leading cause of intensive care unit (ICU) admission and respiratory failure among infants (children aged <1 year) in the United States. In August 2023, CDC's Advisory Committee on Immunization Practices recommended nirsevimab, a long-acting monoclonal antibody, to protect against RSV-associated lower respiratory tract infection among all infants aged <8 months born during or entering their first RSV season. Following licensure, nirsevimab effectiveness has been demonstrated against RSV-associated infant hospitalization, but evidence regarding effectiveness against RSV-associated critical illness is limited. In a 27-hospital case-control investigation, nirsevimab effectiveness against both RSV-associated infant ICU admission and acute respiratory failure (illness requiring continuous positive airway pressure, bilevel positive airway pressure, or invasive mechanical ventilation) after hospital admission was evaluated during December 1, 2024-April 15, 2025. Among 457 case-patients who received a positive RSV test result and 302 control patients who received a negative RSV test result admitted to an ICU with respiratory symptoms, 14% and 45%, respectively, had received nirsevimab ≥7 days before symptom onset. Nirsevimab was 80% effective (95% CI = 70%-86%) against RSV-associated ICU admission and 83% effective (95% CI = 74%-90%) against acute respiratory failure when received a median of 52 days (IQR = 32-89 days) and 50 days (IQR = 32-86 days) before onset for each respective endpoint. These estimates support the recommendation for use of nirsevimab as a prevention strategy to protect infants against severe outcomes from RSV infection.
科研通智能强力驱动
Strongly Powered by AbleSci AI